巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Erytech Pharma SA

    ERYP
    1.210
    0.150
    11.03%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Erytech Pharma SA - 延遲價格・最後更新於 18/08 7:31
    最高位
    1.250
    最低位
    1.210
    開市價
    --
    前收市價
    1.360
    成交量(千)
    0.30
    成交額(百萬)
    0.00
    買入
    1.190
    賣出
    1.300
    每手股數
    --
    市值(百萬)
    37.53
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    6.588 - 0.960
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Erytech Pharma SA
    證券代碼
    ERYP.US
    所屬板塊
    Biotechnology
    公司業務
    Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.
    發行量
    31016053
    公司總部
    60 Avenue Rockefeller, Batiment Adenine
    公司網址
    https://www.erytech.com
    公司電郵
    investors@erytech.com
    公司電話
    +33 478744438
    暫無內容

    關於

    Erytech Pharma SA(ERYP.US)所屬的行業板塊為Biotechnology。
    Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.
    詳細公司背景可參考: https://www.erytech.com